KR20070086803A - Ｍｒｉ 유도 광역학 암 치료 - Google Patents

Ｍｒｉ 유도 광역학 암 치료 Download PDF

Info

Publication number
KR20070086803A
KR20070086803A KR1020077014910A KR20077014910A KR20070086803A KR 20070086803 A KR20070086803 A KR 20070086803A KR 1020077014910 A KR1020077014910 A KR 1020077014910A KR 20077014910 A KR20077014910 A KR 20077014910A KR 20070086803 A KR20070086803 A KR 20070086803A
Authority
KR
South Korea
Prior art keywords
photosensitizer
contrast agent
target tissue
mri
delivery system
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020077014910A
Other languages
English (en)
Korean (ko)
Inventor
쩡-롱 루
아나가 비아디아
티엔이 커
Original Assignee
유니버시티 오브 유타 리써치 파운데이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유니버시티 오브 유타 리써치 파운데이션 filed Critical 유니버시티 오브 유타 리써치 파운데이션
Publication of KR20070086803A publication Critical patent/KR20070086803A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/146—Peptides, e.g. proteins the peptide being a polyamino acid, e.g. poly-lysine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Radiation-Therapy Devices (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Laser Surgery Devices (AREA)
KR1020077014910A 2004-12-03 2005-12-02 Ｍｒｉ 유도 광역학 암 치료 Withdrawn KR20070086803A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63325504P 2004-12-03 2004-12-03
US60/633,255 2004-12-03

Publications (1)

Publication Number Publication Date
KR20070086803A true KR20070086803A (ko) 2007-08-27

Family

ID=36565853

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077014910A Withdrawn KR20070086803A (ko) 2004-12-03 2005-12-02 Ｍｒｉ 유도 광역학 암 치료

Country Status (9)

Country Link
US (1) US20090076571A1 (cg-RX-API-DMAC7.html)
EP (1) EP1830879B1 (cg-RX-API-DMAC7.html)
JP (1) JP2008522666A (cg-RX-API-DMAC7.html)
KR (1) KR20070086803A (cg-RX-API-DMAC7.html)
AT (1) ATE485836T1 (cg-RX-API-DMAC7.html)
AU (1) AU2005311560A1 (cg-RX-API-DMAC7.html)
CA (1) CA2589881A1 (cg-RX-API-DMAC7.html)
DE (1) DE602005024437D1 (cg-RX-API-DMAC7.html)
WO (1) WO2006060797A2 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5237821B2 (ja) 2005-12-05 2013-07-17 日東電工株式会社 ポリグルタミン酸−アミノ酸結合体および方法
US20080181852A1 (en) * 2007-01-29 2008-07-31 Nitto Denko Corporation Multi-functional Drug Carriers
EP2144631A2 (en) * 2007-04-10 2010-01-20 Nitto Denko Corporation Multi-functional polyglutamate drug carriers
EP2155253A2 (en) * 2007-05-09 2010-02-24 Nitto Denko Corporation Polyglutamate conjugates and polyglutamate-amino acid conjugates having a plurality of drugs
US20100284927A1 (en) * 2007-10-26 2010-11-11 University Of Utah Research Foundation Use of mri contrast agents for evaluating the treatment of tumors
ES2627420T3 (es) * 2009-06-12 2017-07-28 Erasmus University Medical Center Rotterdam Nanofotomedicamentos destinados al tratamiento fotodinámico del cáncer
WO2013119957A1 (en) * 2012-02-10 2013-08-15 Aidan Research And Consulting, Llc Weight reduction through inactivation of gastric orexigenic mediator producing cells
TW201514188A (zh) * 2013-03-13 2015-04-16 Lantheus Medical Imaging Inc 製備釓磷維塞三鈉單水合物之方法
CN114870014B (zh) * 2022-05-18 2023-07-07 南京邮电大学 一种多功能抗肿瘤高分子药物及其制备方法和用途
US20250242170A1 (en) * 2024-01-25 2025-07-31 Todd Frank Ovokaitys Methods and Systems for Improving Photodynamic Therapy by Increasing Depth of Penetration Without Concurrently Increasing Energy Deposition
CN118718024B (zh) * 2024-06-07 2026-06-30 中山大学附属第五医院 一种靶向检测胶原分子结构变性的磁共振造影剂及其制备方法与应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5594136A (en) * 1989-12-21 1997-01-14 Pharmacyclics, Inc. Texaphyrin solid supports and devices
WO1998026747A2 (en) * 1996-12-17 1998-06-25 Terman David S Superantigen based methods and compositions for treatment of diseases
DE19831217A1 (de) * 1998-07-03 2000-01-05 Schering Ag Neue Porphyrinderivate, diese enthaltende pharmazeutische Mittel und ihre Verwendung in der photodynamischen Therapie und MRI-Diagnostik
US6534040B2 (en) * 1999-12-23 2003-03-18 Health Research, Inc. Chlorin and bacteriochlorin-based aminophenyl DTPA and N2S2 conjugates for MR contrast media and radiopharmaceuticals
US20020197648A1 (en) * 2001-05-02 2002-12-26 Silva Robin M. High throughput screening methods using magnetic resonance imaging agents

Also Published As

Publication number Publication date
JP2008522666A (ja) 2008-07-03
DE602005024437D1 (de) 2010-12-09
WO2006060797A3 (en) 2006-08-24
EP1830879A4 (en) 2008-09-17
ATE485836T1 (de) 2010-11-15
WO2006060797A2 (en) 2006-06-08
US20090076571A1 (en) 2009-03-19
EP1830879A2 (en) 2007-09-12
CA2589881A1 (en) 2006-06-08
EP1830879B1 (en) 2010-10-27
AU2005311560A1 (en) 2006-06-08

Similar Documents

Publication Publication Date Title
Yang et al. Tumor microenvironment (TME)-activatable circular aptamer-PEG as an effective hierarchical-targeting molecular medicine for photodynamic therapy
Duo et al. Patient-derived microvesicles/AIE luminogen hybrid system for personalized sonodynamic cancer therapy in patient-derived xenograft models
McCarthy et al. A macrophage‐targeted theranostic nanoparticle for biomedical applications
Zhu et al. Hyperbranched polymers for bioimaging
Liang et al. Theranostic porphyrin dyad nanoparticles for magnetic resonance imaging guided photodynamic therapy
KR101035269B1 (ko) 고분자 유도체-광감작제 복합체를 이용한 새로운 광역학치료제
Wang et al. Multifunctional biodegradable polyacrylamide nanocarriers for cancer theranostics-A “see and treat” strategy
EP2437653B1 (en) Paa nanoparticles for enhancement of tumor imaging
US20090311182A1 (en) Macromolecular Delivery Systems for Non-Invasive Imaging, Evaluation and Treatment of Arthritis and Other Inflammatory Diseases
JPWO2002066061A1 (ja) 光増感剤を含有する超音波治療用活性酸素発生剤
CN110856750B (zh) pH敏感缀合物、胶束及其制备方法和用途
Vaidya et al. Contrast enhanced MRI‐guided photodynamic therapy for site‐specific cancer treatment
Zuluaga et al. Selective photodetection and photodynamic therapy for prostate cancer through targeting of proteolytic activity
EP1830879B1 (en) Mri guided photodynamic therapy for cancer
Ding et al. NIR-II-triggered photothermal therapy with Au@ PDA/PEG-PI for targeted downregulation of PSMA in prostate cancer
CN111195352A (zh) 基于岩藻多糖的诊断治疗剂组合物
Bourdon et al. Biodistribution of meta-tetra (hydroxyphenyl) chlorin incorporated into surface-modified nanocapsules in tumor-bearing mice
CN107337685B (zh) 叶酸靶向Pyro光敏的合成和应用
CN118496311A (zh) 具有肿瘤靶向性及近红外荧光成像功能的化合物的制备方法及其应用
US8906343B2 (en) PAA nanoplatforms containing fluorophores and targeted moieties covalently linked and photosensitizer post-loaded
US20240123092A1 (en) Photosensitizer-peptide conjugate with cleavable linker, and composition for photodynamic diagnosis or treatment comprising same
CN119409770B (zh) 一种高效多肽光敏剂及其制备方法与应用
Potter et al. Efficient and highly biocompatible 8-arm PEG-Chlorin e6 nanosystems for 2-photon photodynamic therapy of adrenergic disorders
KR102238174B1 (ko) 후코이단 기반의 쎄라그노시스 조성물
Lange et al. Cyclopeptidic-based Protease-sensitive Photosensitizer Prodrugs for Selective Photodynamic Therapy

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20070629

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid